Streetbeat News

Partnerships

TNDM

Tandem Diabetes Care has launched the t:slim X2 insulin pump software in the U.S., which integrates with Dexcom's G7 Continuous Glucose Monitoring (CGM) system. This marks the first automated insulin delivery system to feature Dexcom's most advanced CGM technology.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 1:39 pm

NVDA

Nvidia Corp (NASDAQ:NVDA) is working to ensure its new chips for the Chinese market comply with U.S. export restrictions. Nvidia dominates China's AI chip market but faces challenges from U.S. curbs and Chinese competitors like Huawei. The company delayed a new AI chip launch in China until next year, aiming to adhere to U.S. regulations. Nvidia's sales in China account for 20% of its revenue, with additional sales in Singapore. Nvidia is also investing in Singapore's AI ecosystem and planning to enhance Japan's AI capabilities through partnerships and an AI research lab. NVDA stock rose 1.09% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

December 06, 2023 | 1:38 pm

FXI

MSFT

China's Commerce Minister met with Microsoft's President, encouraging multinational companies like Microsoft to continue their business in China for mutual benefit. The Minister expressed hope for Microsoft to contribute positively to Sino-US relations.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 1:23 pm

MNTS

Momentus Inc. (NASDAQ:MNTS) has signed a contract with CalgaryToSpace for orbital delivery services in 2025. Momentus will transport CTS-SAT-1, a satellite with two payloads developed at the University of Calgary, to study auroral arcs and test a new 3D printing technique for carbon fiber booms. This contract is Momentus' seventh since August, with previous agreements including AVS, FOSSA, Aarhus, C3S, SatRev, and RIDE! space. Momentus is also preparing for SpaceX Transporter-11 and Transporter-12 missions in 2024 and offers various in-space services and satellite buses.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 1:17 pm

BVS

CVS

Bioventus (BVS) has secured a nationwide contract with Aetna Medicare Advantage Plans, owned by CVS Health (CVS), for its DUROLANE product used in the treatment of knee osteoarthritis. The financial terms of the agreement have not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 1:16 pm

BNGO

Bionano Genomics, Inc. (NASDAQ:BNGO) announced its participation in the American Society of Hematology (ASH) Annual Meeting with presentations and posters featuring the utility of optical genome mapping (OGM) in blood cancer research. Dr. Enze Liu will present a study on OGM's ability to detect structural variants in multiple myeloma. The conference, held in San Diego and online from December 9-12, 2023, will include 13 posters on OGM applications in various hematological conditions.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 1:13 pm

ORA

Ormat Technologies, Inc. (NYSE:ORA) has signed a 25-year Power Purchase Agreement with Dominica Electricity Services Ltd. for a 10 MW geothermal power plant in Dominica, expected to be operational by 2025. The project aligns with Ormat's growth plans and will utilize operational synergies with its Bouillante power plant in Guadeloupe. The development will increase Ormat's Caribbean capacity to 35 MW and support regional transition from fossil fuels. Ownership of the plant will transfer to the Dominica government at the end of the term.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 1:13 pm

AWH

Aspira Women's Health Inc. (AWH) has completed the design of EndoCheck, a blood test for localized endometriosis, and plans a commercial launch in 2024. The test shows promise as a non-invasive alternative to laparoscopic surgery for diagnosing endometriomas. Aspira is collaborating with The University of Oxford and The Dana Farber Cancer Institute for validation and research. The company is also developing EndoMDx for broader endometriosis indications and is in talks with potential partners to drive shareholder value. An Analyst Day event is scheduled for January 2024.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 1:08 pm

OTLK

Outlook Therapeutics has announced a strategic realignment of its resources to focus on regulatory and commercial priorities for ONS-5010 in the US and EU. Joel Prieve, previously SVP of Commercial Operations, is now SVP of Licensing and M&A. Terry Dagnon, former COO, has transitioned to Senior Advisor. The company is collaborating with the FDA to design a new clinical trial to support the ONS-5010 BLA resubmission.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 1:08 pm

NPWR

NET Power, a company specializing in low-carbon power generation, has entered into a strategic supplier agreement with Lummus Technology, a global provider of process technologies and value-driven solutions. Under this agreement, Lummus will supply heat transfer equipment, which is crucial for NET Power's proprietary Allam-Fetvedt Cycle technology. This technology enables power generation with near-zero emissions. The partnership aims to enhance the deployment of NET Power's technology globally, leveraging Lummus' extensive experience and presence in the energy sector.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 12:33 pm